PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for patients with other atherosclerotic localisation, clinical trials results

bezafibrate versus placebo
LEADER, 2002
bezafibrate 400 mg daily
versus
placebo
men with lower extremity arterial diseasedouble-blind
Follow-up duration: 4.6y
UK
clofibrate versus placebo
Acheson, 1972
clofibrate
versus
placebo
cerebral vascular disease NA
Follow-up duration: 6 years
UK
Begg, 1971
clofibrate
versus
placebo
peripheral arteriopathy
Follow-up duration: 3.5 y
VA Neurology Section, 1974
clofibrate
versus
placebo
treatment of cerebrovascular disease
Follow-up duration: 1.8 years
USA
estrogen versus placebo
VA Neurology Section (estrogen), 1966
estrogen
versus
placebo

Follow-up duration: 1.4 years
fluvastatin versus placebo
BCAPS, 2001
fluvastatin 40 mg once daily
versus
placebo
subjects who had carotid plaque but no symptoms of carotid artery diseasedouble-blind
Follow-up duration: 3.0 years
Sweden
lovastatin versus placebo
ACAPS, 1994
NCT00000469
lovastatin 20mg daily
versus
placebo
men and women, 40 to 79 years old, with early carotid atherosclerosis and moderately elevated LDL cholesterol.double blind
Follow-up duration: 2.8 years
USA
policosanol versus control
Castano, 2001
policosanol 10 mg twice daily
versus
placebo
intermittent claudicationdouble-blind
Follow-up duration: 2 years
pravastatin versus placebo
CAIUS, 1996
pravastatin 40mg/d
versus
placebo
asymptomatic patients with hypercholesterolemia and at least one 1.3 < IMT < 3.5 mm in the carotid arteriesdouble blind
Follow-up duration: 3 years
Italy

  Options


in first

in second

  Filter